NCT04746599 is a NA clinical trial of Autologous Fat Grafting in Critical Limb Ischemia, sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico.

Who is sponsoring NCT04746599?

NCT04746599 is sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico.

What drugs are being tested in NCT04746599?

Interventions in NCT04746599: Autologous Fat Grafting.

What condition does NCT04746599 study?

NCT04746599 studies Critical Limb Ischemia, Peripheral Arterial Disease - PAD, Ischemic Ulcer, Ischemic Feet, Diabetic Foot, Scleroderma, Systemic, Thrombo Angiitis Obliterans, Ischemic Leg.

Is NCT04746599 still recruiting?

NCT04746599 is currently status unknown. Last updated 10 February 2021.

Last reviewed 2021-02-10 · How we verify

NCT04746599

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Autologous Fat Grafting in the Treatment of Critical Limb Ischaemia

Status unknown NA Last updated 10 February 2021

What this trial tests

NA trial testing Autologous Fat Grafting in Critical Limb Ischemia in 20 participants. Status unknown.

Timeline

1 January 2021

Primary endpoint
30 June 2022

31 December 2022

Quick facts

Lead sponsor	Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 January 2021
Primary completion	30 June 2022
Estimated completion	31 December 2022
Sites	1 location across Italy

Drugs / interventions tested

Autologous Fat Grafting

Conditions studied

Critical Limb Ischemia — all drugs for Critical Limb Ischemia →
Peripheral Arterial Disease - PAD — all drugs for Peripheral Arterial Disease - PAD →
Ischemic Ulcer — all drugs for Ischemic Ulcer →
Ischemic Feet — all drugs for Ischemic Feet →

Sponsor

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Who can join

18 and older, any sex, with Critical Limb Ischemia or Peripheral Arterial Disease - PAD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Critical Limb Ischaemia (CLI) is a condition characterized by chronic ischemic at-rest pain, ulcers, or gangrene for more than 2 weeks in one or both legs, attributable to objectively proven arterial occlusive disease.CLI is associated with a high risk of lower amputation, diminished quality of life and mortality. Revascularization by either bypass surgery or endovascular recanalization is considered the first-choice treatment in patients with CLI. Revascularization is not always possible because patients with CLI often have severe comorbidities or because it is not technically feasible. On the basis of their well-recognized regenerative and angiogenetic properties, cell therapy with autologous bone marrow-derived mesenchymal stem cells (BMMSCs) has been proposed and tested in different animal models and in some human pathological conditions characterized by peripheral ischemia and wound formation.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Emerging roles of mesenchymal stem cell therapy in patients with critical limb ischemia.
Shirbaghaee Z, Hassani M, Heidari Keshel S, Soleimani M. · · 2022 · cited 36× · PMID 36068595 · DOI 10.1186/s13287-022-03148-9

Verify or expand the search:

Other trials of Autologous Fat Grafting

Trials testing the same drug.

NCT07480447 — Comparison of Pain Reduction in Painful Chronic Wounds With and Without Fat Grafting · NA · not yet recruiting

Other recruiting trials for Critical Limb Ischemia

Currently open trials in the same condition.

NCT04433572 — Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee · Phase 3 · recruiting
NCT06434194 — Serrantor OCT Study · NA · recruiting
NCT06482892 — TP03HN106 in Patients With Critical Limb Ischemia · Phase 2 · recruiting
NCT06296576 — Acceleration Time Assessment for Prediction of Critical Limb Ischemia · recruiting
NCT06075940 — Evaluation of the MAGNITUDE® Bioresorbable Drug-Eluting Scaffold in the Treatment of Patients With Below the Knee Diseas · NA · recruiting

Other Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico trials

Trials by the same sponsor.

NCT07492433 — Risk Factors, Incidence, and Clinical Impact of Intraluminal Thrombosis Following FET and TEVAR · not yet recruiting
NCT07402174 — EIT- Guided Lung Recruitment in pARDS · NA · not yet recruiting
NCT07234097 — The Influence of Music on perceiVed paIn and leVels of Anxiety whiLe unDergoing transperIneal Prostate Biopsy: the VIVAL · NA · not yet recruiting
NCT07317193 — DEFINING THE GENETIC DRIVERS OF ADULT-ONSET CHOLESTATIC LIVER DISEASE · NA · recruiting
NCT07487961 — Assess Abdominal Aortic Diameter in Females · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04746599 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Last refreshed: 10 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04746599.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing